RhumbLine Advisers
TXMD icon

RhumbLine Advisers’s TherapeuticsMD TXMD Stock Holding History

RhumbLine Advisers’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-122
Closed -$196 – 4329
2024
Q2 		$196 Sell
122
-18
-13% -$36 ﹤0.01% 4319
2024
Q1 		$320 Hold
140
– – ﹤0.01% 4202
2023
Q4 		$314 Hold
140
– – ﹤0.01% 4219
2023
Q3 		$422 Hold
140
– – ﹤0.01% 4239
2023
Q2 		$576 Buy
+140
New +$549 ﹤0.01% 4315
2022
Q2 		– Sell
-6,251
Closed -$119K – 3238
2022
Q1 		$119K Buy
6,251
+288
+5% +$4.53K ﹤0.01% 2857
2021
Q4 		$106K Sell
5,963
-137
-2% -$4.11K ﹤0.01% 2934
2021
Q3 		$226K Buy
6,100
+398
+7% +$17.7K ﹤0.01% 2865
2021
Q2 		$339K Sell
5,702
-690
-11% -$41.8K ﹤0.01% 2738
2021
Q1 		$428K Buy
6,392
+510
+9% +$39.9K ﹤0.01% 2562
2020
Q4 		$356K Sell
5,882
-794
-12% -$54.2K ﹤0.01% 2594
2020
Q3 		$527K Sell
6,676
-922
-12% -$73.5K ﹤0.01% 2268
2020
Q2 		$475K Buy
7,598
+1,913
+34% +$111K ﹤0.01% 2369
2020
Q1 		$301K Sell
5,685
-348
-6% -$34.5K ﹤0.01% 2404
2019
Q4 		$730K Buy
6,033
+289
+5% +$41.6K ﹤0.01% 2219
2019
Q3 		$1.04M Buy
5,744
+125
+2% +$17.6K ﹤0.01% 2018
2019
Q2 		$730K Buy
5,619
+830
+17% +$149K ﹤0.01% 2204
2019
Q1 		$1.17M Sell
4,789
-14
-0.3% -$3.7K ﹤0.01% 1965
2018
Q4 		$915K Buy
4,803
+1,633
+52% +$398K ﹤0.01% 2060
2018
Q3 		$1.04M Sell
3,170
-133
-4% -$40.7K ﹤0.01% 1989
2018
Q2 		$1.03M Buy
3,303
+181
+6% +$55.3K ﹤0.01% 1996
2018
Q1 		$760K Buy
3,122
+60
+2% +$16.8K ﹤0.01% 2059
2017
Q4 		$925K Sell
3,062
-654
-18% -$182K ﹤0.01% 1985
2017
Q3 		$983K Buy
3,716
+48
+1% +$13.9K ﹤0.01% 1987
2017
Q2 		$967K Buy
3,668
+124
+3% +$31.1K ﹤0.01% 1963
2017
Q1 		$1.28M Buy
3,544
+194
+6% +$60K ﹤0.01% 1805
2016
Q4 		$966K Buy
3,350
+156
+5% +$48.3K ﹤0.01% 1870
2016
Q3 		$1.09M Buy
3,194
+51
+2% +$18.6K ﹤0.01% 1761
2016
Q2 		$1.34M Buy
3,143
+350
+13% +$144K ﹤0.01% 1609
2016
Q1 		$894K Buy
2,793
+263
+10% +$89.7K ﹤0.01% 1868
2015
Q4 		$1.31M Buy
2,530
+311
+14% +$115K ﹤0.01% 1627
2015
Q3 		$650K Buy
2,219
+84
+4% +$29.9K ﹤0.01% 2056
2015
Q2 		$839K Sell
2,135
-25
-1% -$8.82K ﹤0.01% 1984
2015
Q1 		$654K Buy
2,160
+536
+33% +$131K ﹤0.01% 2127
2014
Q4 		$361K Buy
1,624
+56
+4% +$11.6K ﹤0.01% 2478
2014
Q3 		$364K Buy
1,568
+50
+3% +$12.6K ﹤0.01% 2404
2014
Q2 		$335K Buy
1,518
+224
+17% +$49.8K ﹤0.01% 2527
2014
Q1 		$408K Sell
1,294
-76
-6% -$24.2K ﹤0.01% 2349
2013
Q4 		$357K Buy
1,370
+14
+1% +$3.07K ﹤0.01% 2472
2013
Q3 		$199K Sell
1,356
-12
-0.9% -$1.45K ﹤0.01% 2785
2013
Q2 		$207K Buy
+1,368
New +$187K ﹤0.01% 2963

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's TXMD Position: Q3 2024 in Review

RhumbLine Advisers sold out of TherapeuticsMD (TXMD) in Q3 2024, closing a stake of 122 shares — an estimated $196 sold.

RhumbLine Advisers first reported a position in TXMD in Q2 2013 and held it in 41 quarters. The position peaked at $1.34M in Q2 2016. 37 funds tracked by Wall St. Rank hold TXMD as of Q3 2024.

  • RhumbLine Advisers reported no remaining TherapeuticsMD position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 122 TherapeuticsMD shares in Q3 2024, an estimated $196.
  • RhumbLine Advisers first reported a position in TherapeuticsMD in Q2 2013 and held it in 41 quarters.
  • RhumbLine Advisers's TherapeuticsMD position peaked at $1.34M in Q2 2016.
  • 37 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.